Monofloxofta (Ofloxacin)

Ofloxacin belongs to the fluoroquinolone class and works by inhibiting two essential bacterial enzymes, DNA gyrase and topoisomerase IV. These enzymes are required for DNA replication and transcription. By blocking their activity, Ofloxacin prevents bacterial cell division, leading to bacterial death and resolution of the infection.

The dosing regimen for Monofloxofta is determined by the prescribing clinician based on the specific infection, severity, and patient factors. The prescriber will specify the number of drops, frequency, and duration of therapy on the prescription label.

Safety data for topical Ofloxacin during pregnancy and lactation are limited. The decision to use Monofloxofta in pregnant or nursing women should be made after a careful risk‑benefit assessment by the healthcare professional, considering the severity of the eye infection and available alternatives.

To order Monofloxofta, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Monofloxofta (Ofloxacin) offers broad‑spectrum activity against many Gram‑negative and Gram‑positive ocular pathogens, similar to other fluoroquinolone eye drops such as ciprofloxacin. Compared with older agents like chloramphenicol, Ofloxacin generally provides faster bacterial eradication and a lower risk of resistance, though choice depends on local susceptibility patterns and patient tolerance.

Monofloxofta should be stored at room temperature, below 25 °C, in its original container. Protect the product from direct light and moisture. Do not freeze the solution, and keep the vial tightly closed when not in use to maintain sterility.

Monofloxofta is applied as eye drops. The patient should wash their hands, tilt the head back, pull down the lower eyelid to form a pocket, and instill the prescribed number of drops into the conjunctival sac. The eye should be closed gently for a few seconds to allow distribution, and contact lenses should be removed during treatment.

Serious risks, although rare, include severe allergic reactions such as swelling or rash around the eye, corneal ulceration or worsening of existing corneal lesions, significant eye pain, and in extremely rare cases, systemic hypersensitivity reactions like Stevens‑Johnson syndrome. Any of these symptoms require immediate discontinuation and medical evaluation.

Monofloxofta should not be used by individuals with a known hypersensitivity to Ofloxacin, other fluoroquinolones, or any component of the ophthalmic formulation. Patients with a history of severe ocular surface disease or those who have experienced serious adverse reactions to fluoroquinolone eye drops should avoid its use.